2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-113006
    3-Methylglutarylcarnitine 102673-95-0 99%
    3-Methylglutarylcarnitine is a biomarker of disease associated with compromised mitochondrial energy metabolism.
    3-Methylglutarylcarnitine
  • HY-114509
    Anilazine 101-05-3 98.50%
    Anilazine is a fungicide and inhibit the growth of Rhizobium sp. and E. coli. Anilazine inhibits glucose oxidation and succinate oxidation and also inhibits in vitro succinic dehydrogenase activity.
    Anilazine
  • HY-114516
    Fructosylvaline 10003-64-2 99.79%
    Fructosylvaline (Fructose Valine) is a model fructosyl-amine (Amadori compound) for glycated hemoglobin. Fructosylvaline can be used as a nitrogen source to cultivate microbial strains.
    Fructosylvaline
  • HY-114853
    BVT.13 756813-87-3 98.44%
    BVT.13 is an orally active and selective PPARγ agonist with a maximal efficacy similar to that of Rosiglitazone (HY-17386). In addition, BVT.13 exhibits antidiabetic activity in ob/ob mice.
    BVT.13
  • HY-117769
    GSK837149A 13616-29-0 99.13%
    GSK837149A is a selective inhibitor of human Fatty Acid Synthase (FASN) targeting the KR domain. GSK837149A has reversible inhibition effect on FASN and selectivity for type I FASN (Ki=30 nM). GSK837149A is also a competitive inhibitor of NADPH and a non-competitive inhibitor of acetoacetyl-CoA. GSK837149A can be used for the research of obesity and breast cancer.
    GSK837149A
  • HY-120651
    LDL-IN-2 778624-05-8 99.0%
    LDL-IN-2 (compound 3) is an antioxidant against copper mediated low-density lipoproteins (LDL) oxidation.
    LDL-IN-2
  • HY-122056
    1,2-Diheptanoyl-SN-glycero-3-phosphocholine 39036-04-9 99.81%
    1,2-Diheptanoyl-SN-glycero-3-phosphocholine (L-α-Diheptanoyllecithin; 12-Diheptanoyl-sn-glycero-3-PC) is an ester product.
    1,2-Diheptanoyl-SN-glycero-3-phosphocholine
  • HY-122949
    Momordicine I 91590-76-0
    Momordicine I is a cucurbitane-type triterpenoids. Momordicine I suppresses glioma growth by promoting apoptosis and impairing mitochondrial oxidative phosphorylation. Momordicine I inhibits glycolysis, lipid metabolism, induces autophagy in HNC cells to suppress head and neck cancer growth. Momordicine I alleviates isoproterenol-induced cardiomyocyte hypertrophy through suppression of PLA2G6 and DGK-ζ. Momordicine I exerts its cardiovascular benefits by upregulating nitric oxide, inhibiting the activity of angiotensin-converting enzyme (ACE), activating the PI3K/Akt pathway, reducing oxidative stress and inflammation. Momordicine I inhibits AKT1, IL-6, and SRC, suggesting its potential application in type 2 diabetes.
    Momordicine I
  • HY-124177
    C14 Ceramide 34227-72-0 99.89%
    C14 Ceramide is an ester product.
    C14 Ceramide
  • HY-125910
    Cholesteryl Linolenate 2545-22-4 99.90%
    Cholesteryl Linolenate is an endogenous metabolite.
    Cholesteryl Linolenate
  • HY-126720
    N-Lignoceroyl Taurine 807370-75-8 99.0%
    N-Lignoceroyl Taurine is an arachidonoyl amino acid and taurine conjugate with a fatty acid that can be isolated from bovine brain. N-Lignoceroyl Taurine is one of several novel taurine-conjugated fatty acids discovered during mass spectrometry lipidomic analysis of the brain and spinal cord of wild-type and fatty acid amide hydrolase (FAAH) knockout mice. N-Lignoceroyl Taurine levels were 23-26-fold higher in FAAH-/- mice compared to wild-type mice, suggesting that FAAH utilizes N-Lignoceroyl Taurine as a substrate. However, in vitro experiments with purified FAAH showed that N-Lignoceroyl Taurine was hydrolyzed 2,000-fold slower in FAAH compared to oleoylethanolamide. N-Acyl Taurines with polyunsaturated acyl chains can activate members of the transient receptor potential (TRP) calcium channel family, including TRPV1 and TRPV4.
    N-Lignoceroyl Taurine
  • HY-129697
    3-Hydroxy Medetomidine 128366-50-7 ≥98.0%
    3-Hydroxy Medetomidine (3-OH Medetomidine; Medetomidine metabolite MIII) is a metabolite of the α2-adrenergic receptor agonist medetomidine.
    3-Hydroxy Medetomidine
  • HY-130289
    (±)4-HDHA 90906-40-4 99.05%
    (±)4-HDHA (4-Hydroxy docosahexaenoic acid) is an autoxidation product of Docosahexaenoic acid (HY-B2167) (DHA). (±)4-HDHA is a PPARγ agonist, antidiabetic and anti-inflammatory agent.
    (±)4-HDHA
  • HY-131309
    12-Doxylstearic acid 29545-47-9 99.00%
    12-Doxyl stearic acid is a form of stearic acid that contains a 4,4-dimethyl-3-oxazolinyloxy (DOXYL) group, creating a hydrophobic spin label. It is commonly used to study molecular aspects of membranes and hydrophobic proteins.
    12-Doxylstearic acid
  • HY-131652
    1,2-Di-O-hexadecyl-sn-glycero-3-phosphocholine 36314-47-3
    1,2-Di-O-hexadecyl-sn-glycero-3-phosphocholine (16:0 Diether PC) is a synthetic ether-linked phospholipid containing hexadecyl groups at the sn-1 and sn-2 positions. It is commonly used in the generation of liposomes and artificial membranes to study membrane dynamics.
    1,2-Di-O-hexadecyl-sn-glycero-3-phosphocholine
  • HY-135604
    Dibutyl phosphate 107-66-4 98.0%
    Dibutyl phosphate (DBUP) is a urinary metabolite of organophosphate esters (OPEs). Dibutyl phosphate is positively correlated with an increased risk of sarcopenia.
    Dibutyl phosphate
  • HY-137261
    UDP-β-D-glucose disodium 7333-33-7 99.9%
    UDP-β-D-glucose disodium acts as a glycosyl donor and biosynthetic intermediate, and is also a stereoisomer of UDP-α-D-glucose.
    UDP-β-D-glucose disodium
  • HY-138068
    L-Tryptophanylglycine 7360-09-0 99.93%
    L-Tryptophanylglycine is a dipeptide. L-Tryptophanylglycine exerts its function through competitive substrate interaction with intestinal dipeptide transporters.
    L-Tryptophanylglycine
  • HY-139314
    A2B receptor antagonist 2 784-90-7 99.60%
    A2B receptor antagonist 2 (compound 18) is an adenosine receptor A2B antagonist, with Ki values of 2.30 μM, 6.8 μM and 3.44 μM for rA1, rA2A and hA2B, respectively.
    A2B receptor antagonist 2
  • HY-142080
    Pimeloyl-CoA 18907-20-5
    Pimeloyl-CoA is a key precursor compound in the biotin synthesis pathway, which can promote the de novo synthesis of biotin. Pimeloyl-CoA is mainly used in the study of microbial metabolic mechanisms, especially the analysis of biotin synthesis pathways and basic research on the biosynthesis of related antibiotics or vitamins.
    Pimeloyl-CoA
Cat. No. Product Name / Synonyms Application Reactivity